Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of inflammation in mood disorders has received increased attention. There is substantial evidence that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced depression. METHODS: We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase (COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 (FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate analysis. RESULTS: The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history (p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness (p = 0.0200 HR = 1.14), disorderliness (p = 0.0339, HR = 1.11), and low scores on extravagance (p = 0.0040, HR = 0.85). An interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype (HR = 3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) were associated with depression. CONCLUSIONS: The results of the study support the theory that IFN-induced depression is associated with a complex pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden our understanding of the pathogenesis of mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A psychobiological model of temperament and character
Cloninger, C. R. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820240059008 · Cited by 5,458 · cited 1×
“The biopsychosocial model by Cloninger et al.”
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“The role of inflammation in mood disorders has received increased attention (Dowlati et al., 2010; Moylan et al., 2013; Zhang et al., 2015).”
BackgroundChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population
Herrero, M. J., Blanch, J., Peri, J. M., De Pablo, J., Pintor, L., & Bulbena, A. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00043-4 · Cited by 892 · cited 1×
“In this study, the validated Spanish version of the HADS was used (Herrero et al., 2003).”
MethodMajor depressive disorder and hypothalamic-pituitary-adrenal axis activity
Vreeburg, S. A., Hoogendijk, W. J. G., van Pelt, J., DeRijk, R. H., Verhagen, J. C. M., van Dyck, R., Smit, J. H., Zitman, F. G., & Penninx, B. W. J. H. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.50 · Cited by 792
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Role of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667 · cited 1×
“It is likely that neurotrophic factors themselves do not control mood, but that they may be crucial to the modulation of neural networks involved in the pathogenesis of depression, including serotonergic or dopaminergic pathways (Castren et al., 2007; Groves, 2007).”
BackgroundDiez-Quevedo, C., Rangil, T., Sanchez-Planell, L., Kroenke, K., & Spitzer, R. L. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00021 · Cited by 649 · cited 1×
“The validated Spanish version of the PHQ is designed to screen depressive and other psychiatric disorders in primary care and other medical settings (Diez-Quevedo et al., 2001; Navines et al., 2012).”
BackgroundRaison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“…in the CNS may modulate monoamine neurotransmission (Raison et al., 2009), alter the glucocorticoid axis, and dysregulate apoptotic mechanisms (Cai et al., 2005; Asnis and De La Garza, 2006; Raison et al., 2010a), which are factors related with the onset of clinical depression (Anisman, 2009).”
BackgroundMoylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Verhagen, M., van der Meij, A., van Deurzen, P. A. M., Janzing, J. G. E., Arias-Vásquez, A., Buitelaar, J. K., & Franke, B. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.109 · Cited by 470 · cited 1×
“As described in previous studies and metaanalyses, the association between the BDNF Val66Met polymorphism and different psychiatric conditions is complex (Groves, 2007; Verhagen et al., 2010).”
ResultMidbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype
Meyer-Lindenberg, A., Kohn, P. D., Kolachana, B., Kippenhan, S., McInerney-Leo, A., Nussbaum, R., Weinberger, D. R., & Berman, K. F. (2005) · Nature Neuroscience · doi:10.1038/nn1438 · Cited by 428 · cited 1×
“On the other hand, dopamine plays a critical role in prefrontal cortex function in an inverted U-shaped manner, with both too much and too little dopamine being associated with a higher risk of depression (Meyer-Lindenberg et al., 2005; Honea et al., 2009).”
BackgroundGratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428
Self-citationWebster, M. J., Knable, M. B., O'Grady, J., Orthmann, J., & Weickert, C. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001139 · Cited by 420 · cited 1×
“Hence, a reduction in glucocorticoid receptor mRNA levels has been reported in patients with major depression (Webster et al., 2002; Perlman et al., 2004).”
BackgroundCapuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J., Vogt, G. J., Massung, B., & Miller, A. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.010 · Cited by 367 · cited 2×
“A high concentration of proinflammatory cytokines with activity in the CNS may modulate monoamine neurotransmission (Raison et al., 2009), alter the glucocorticoid axis, and dysregulate apoptotic mechanisms (Cai et al., 2005; Asnis and De La Garza, 2006; Raison et al., 2010a), which are factors…”
BackgroundCapuron, L., Raison, C. L., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1342 · Cited by 308
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297 · cited 4×
“Previous studies and meta-analyses have shown several risk factors for IFN-induced depression, including clinical factors such as subthreshold depressive symptoms at baseline, a history of depression, and certain personality traits, as well as sociodemographic factors such as female gender and low educational level (R…”
BackgroundResultInfluentialSelf-citationAnisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292 · cited 3×
“…in the CNS may modulate monoamine neurotransmission (Raison et al., 2009), alter the glucocorticoid axis, and dysregulate apoptotic mechanisms (Cai et al., 2005; Asnis and De La Garza, 2006; Raison et al., 2010a), which are factors related with the onset of clinical depression (Anisman, 2009).”
BackgroundIntegrative Psychobiological Approach to Psychiatric Assessment and Treatment
Cloninger, C. R., & Svrakic, D. M. (1997) · Psychiatry · doi:10.1080/00332747.1997.11024793 · Cited by 262
Jiang, X., Xu, K., Hoberman, J., Tian, F., Marko, A. J., Waheed, J. F., Harris, C. R., Marini, A. M., Enoch, M.-A., & Lipsky, R. H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300703 · Cited by 244
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Raison, C. L., Borisov, A. S., Woolwine, B. J., Massung, B., Vogt, G., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.58 · Cited by 183
Menke, A., Klengel, T., Rubel, J., Brückl, T., Pfister, H., Lucae, S., Uhr, M., Holsboer, F., & Binder, E. B. (2013) · Genes, Brain and Behavior · doi:10.1111/gbb.12026 · Cited by 151 · cited 1×
“…cortisol levels by desensitizing glucocorticoid receptors (GCR1 and GCR2; Cai et al., 2005; Silverman and Sternberg, 2012) that may be modulated by proteins such as FK506-binding protein 5 (FKBP5), which is a co-chaperone of the glucocorticoid receptors (Menke et al., 2013; Höehne et al., 2014).”
BackgroundImpact of interacting functional variants in COMT on regional gray matter volume in human brain
Honea, R., Verchinski, B. A., Pezawas, L., Kolachana, B. S., Callicott, J. H., Mattay, V. S., Weinberger, D. R., & Meyer-Lindenberg, A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.064 · Cited by 128
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100 · cited 1×
“Previous studies have reported that high harm-avoidance, low selfdirection, and high neuroticism may be related to IFN-induced depression (Lotrich et al., 2007; Castellvi et al., 2009).”
BackgroundLongitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression
Lok, A., Mocking, R. J. T., Ruhé, H. G., Visser, I., Koeter, M. W. J., Assies, J., Bockting, C. L. H., Olff, M., & Schene, A. H. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.10.005 · Cited by 99
Lotrich, F. E., Albusaysi, S., & Ferrell, R. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.263 · Cited by 92
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84 · cited 1×
“Given that some patients are more likely to present depression during treatment with cytokines such as interferon alpha (IFN-alpha), research has focused on identifying social, clinical, and biological factors that may lead to neuropsychiatric side effects (Smith et al., 2012).”
BackgroundHohne, N., Poidinger, M., Merz, F., Pfister, H., Bruckl, T., Zimmermann, P., Uhr, M., Holsboer, F., & Ising, M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu087 · Cited by 74
Cited by
Guida, F., Turco, F., Iannotta, M., De Gregorio, D., Palumbo, I., Sarnelli, G., Furiano, A., Napolitano, F., Boccella, S., Luongo, L., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.001 · Cited by 367
Psychiatry in the aftermath of COVID-19
Vieta, E., Pérez, V., & Arango, C. (2020) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2020.04.004 · Cited by 277
Self-citationRecurrence of depressive disorders after interferon-induced depression
Chiu, W.-C., Su, Y.-P., Su, K.-P., & Chen, P.-C. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.274 · Cited by 80
Salagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Self-citationDementia with Lewy bodies: Challenges in the diagnosis and management
Chin, K. S., Teodorczuk, A., & Watson, R. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835029 · Cited by 63
Metadata
- Authors
- Udina, M., Navinés, R., Egmond, E., Oriolo, G., Langohr, K., Gimenez, D., Valdés, M., Gómez-Gil, E., Grande, I., Gratacós, M., Kapczinski, F., Artigas, F., Vieta, E., Solà, R., & Martín-Santos, R.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-30
- Volume
- 19
- Issue
- 4
- Pages
- pyv135
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2214064021
- Cited by
- 88
- References
- 32
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.